U.S. markets open in 3 hours 47 minutes

Danaher Corporation (DAP.DE)

XETRA - XETRA Precio retrasado. Moneda en EUR.
Añadir a la lista de seguimiento
249.35+0.40 (+0.16%)
A partir del 09:57AM CEST. Mercado abierto.

Danaher Corporation

2200 Pennsylvania Avenue, North West
Suite 800 West
Washington, DC 20037-1701
United States
202 828 0850
https://www.danaher.com

Sector(es)Healthcare
IndustriaDiagnostics & Research
Empleados a tiempo completo61,000

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Steven M. RalesCo-Founder & ChairmanN/DN/D1951
Mr. Rainer M. BlairPresident, CEO & Director4.76MN/D1964
Mr. Mitchell P. RalesCo-Founder & DirectorN/DN/D1957
Mr. Matthew R. McGrewCFO & Executive VP2.29MN/D1972
Dr. Jose-Carlos Gutierrez-Ramos Ph.D.Senior VP & Chief Science Officer1.87MN/D1962
Ms. Georgeann F. CoucharaSenior Vice President of Human Resources1.49MN/D1977
Mr. Christopher M. BoudaVP & Chief Accounting OfficerN/DN/DN/D
Mr. John BedfordVice President of Investor RelationsN/DN/DN/D
Mr. Brian W. EllisSenior VP, General Counsel & Chief Compliance Officer1.73MN/D1967
Mr. Daniel A. Raskas J.D.Senior Vice President of Corporate DevelopmentN/DN/D1967
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Gestión corporativa

La calificación ISS Governance QuickScore de Danaher Corporation a partir del 1 de octubre de 2024 es 7. Las puntuaciones principales son Auditoría: 9; Junta: 10; Derechos del accionista: 2; Compensación: 1.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.